成人血清阴性重症肌无力中先天性肌无力综合征的二代测序筛查
本研究对50例成人血清阴性重症肌无力(SNMG)患者进行全外显子测序,发现14%的患者被基因诊断为先天性肌无力综合征(CMS),其中CHRNE变异4例、RAPSN变异3例。部分CMS患者对免疫治疗有主观反应,提示遗传学检测对治疗决策有重要意义。
要点
- 成人SNMG患者中14%经WES确诊CMS,以CHRNE和RAPSN变异为主。
- CMS患者对免疫治疗的主观反应不能排除遗传病因。
- 对血清阴性肌无力综合征患者提供基因检测可能改变治疗策略。
核心结论
- 相当比例的SNMG患者存在遗传性病因,WES可检出CMS。
- 对免疫治疗的主观反应不排除CMS的分子诊断。
研究设计与样本
- 前瞻性队列研究,纳入3家奥地利三级神经肌肉中心2022年8月至2024年1月的50例成人SNMG患者。
- 采用全外显子测序(WES)进行基因筛查,并经全面血清学检测排除相关抗体。
主要发现
- 50例患者中7例(14%)经WES确诊CMS,其中CHRNE变异4例、RAPSN变异3例。
- 4例报告临床意义不确定的变异,涉及CACNA1S、DOK7、DPAGT1和RAPSN。
- 单因素分析中CMS患者发病年龄趋向更年轻(p=0.04,r=0.29),但多重检验校正后无因素显著关联。
- 仅1例确诊CMS患者报告阳性家族史。
- 6例(86%)CMS患者曾接受免疫调节治疗(n=4)或胸腺切除术(n=4);4例接受免疫治疗者中3例至少部分有效。
临床怎么用
- 对血清阴性肌无力综合征成人患者应考虑提供基因检测以排查CMS。
- 免疫治疗有效不能作为排除CMS的依据。
局限性
- 样本量较小(50例),可能限制统计效能。
- 单因素分析中发病年龄的关联经多重检验校正后不显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Myasthenia gravis (MG) is a disorder of the neuromuscular junction, typically associated with autoantibodies (Abs) that impair neuromuscular transmission. However, approximately 10% of cases are seronegative. Emerging evidence suggests that seronegative MG (SNMG) may be mimicked by hereditary conditions, particularly congenital myasthenic syndromes (CMSs), which require different treatments. In this study, we aimed to determine the proportion of CMS among patients diagnosed with SNMG. METHODS: We used whole-exome sequencing (WES) in adult patients (aged ≥18 years) diagnosed with SNMG who were enrolled at 3 Austrian tertiary neuromuscular centers between August 2022 and January 2024. Genetic testing was conducted in individuals who remained seronegative after comprehensive serologic testing to exclude Abs against (clustered) acetylcholine receptors, muscle-specific kinase, lipoprotein receptor-related protein 4, and voltage-gated calcium channels. Moreover, we aimed to analyze clinical and demographic factors associated with the likelihood of receiving a molecular diagnosis. RESULTS: A total of 50 patients with SNMG (35 [70%] female) were referred for exome-based genetic screening. The median age at disease onset was 35 years (interquartile range 24.0-46.0 years). Seven patients (14%) were genetically diagnosed with CMS through WES (4 with CHRNE and 3 with RAPSN variants). In addition, findings of uncertain clinical significance were reported in 4 cases, implicating CACNA1S, DOK7, DPAGT1, and RAPSN. Although patients with CMS tended to have a younger age at disease onset in univariate analysis (p = 0.04, r = 0.29), no clinical or demographic factors remained significantly associated with a molecular diagnosis after correction for multiple testing. Only 1 patient with a confirmed CMS diagnosis reported a positive family history. Six individuals with CMS (86%) had either received immunomodulatory treatments (n = 4) or undergone thymectomy (n = 4). Of the 4 patients with CMS receiving immunotherapies, 3 were reported to have experienced at least a partial response. DISCUSSION: Our findings provide evidence that a considerable proportion of patients diagnosed with SNMG have an underlying hereditary etiology. Notably, a (subjective) response to immunotherapies does not exclude a molecular CMS diagnosis. In conclusion, offering genetic testing to seronegative patients with myasthenic syndromes may have profound therapeutic implications.
引用
- Krenn M, Wagner M, Schuller H, et al. Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing. Neurology. 2025. PMID: 41004697. doi:10.1212/WNL.0000000000214177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。